Direct-acting antivirals (DAAs), also known as “specifically
targeted antiviral therapy for hepatitis C” (STAT-C), are the most
important new therapeutical options for CHC. In May 2011, two
HCV protease inhibitors Telaprevir (Incivek™) and Boceprevir
(Victrelis™) have been approved by the FDA. For the first time,
we have now drugs with specific anti-HCV activity. Several other
DAAs are at various stages of clinical development, the most
advanced being alternative protease inhibitors and nucleoside
and non-nucleoside polymerase inhibitors. Other tentative
approaches include inhibitors of host cyclophilins, alphaglucosidase
inhibitors, oligonucleotides and immune modulators
(Soriano 2009).
targeted antiviral therapy for hepatitis C” (STAT-C), are the most
important new therapeutical options for CHC. In May 2011, two
HCV protease inhibitors Telaprevir (Incivek™) and Boceprevir
(Victrelis™) have been approved by the FDA. For the first time,
we have now drugs with specific anti-HCV activity. Several other
DAAs are at various stages of clinical development, the most
advanced being alternative protease inhibitors and nucleoside
and non-nucleoside polymerase inhibitors. Other tentative
approaches include inhibitors of host cyclophilins, alphaglucosidase
inhibitors, oligonucleotides and immune modulators
(Soriano 2009).
No comments:
Post a Comment